1. Home
  2. AEI vs LUNG Comparison

AEI vs LUNG Comparison

Compare AEI & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alset Inc. (TX)

AEI

Alset Inc. (TX)

HOLD

Current Price

$1.05

Market Cap

54.1M

Sector

Real Estate

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$1.27

Market Cap

57.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AEI
LUNG
Founded
2014
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Building operators
Industrial Specialties
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
54.1M
57.9M
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
AEI
LUNG
Price
$1.05
$1.27
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$5.38
AVG Volume (30 Days)
8.0K
250.8K
Earning Date
05-14-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
7.64
EPS
N/A
N/A
Revenue
$16,238,200.00
$90,497,000.00
Revenue This Year
N/A
$2.48
Revenue Next Year
N/A
$18.46
P/E Ratio
N/A
N/A
Revenue Growth
N/A
8.01
52 Week Low
$1.05
$1.13
52 Week High
$4.55
$3.39

Technical Indicators

Market Signals
Indicator
AEI
LUNG
Relative Strength Index (RSI) 31.27 43.82
Support Level N/A $1.20
Resistance Level $1.58 $1.65
Average True Range (ATR) 0.10 0.09
MACD -0.01 -0.02
Stochastic Oscillator 0.00 21.84

Price Performance

Historical Comparison
AEI
LUNG

About AEI Alset Inc. (TX)

Alset Inc is a diversified holding company engaged through its subsidiaries in the development of EHome communities and other real estate, financial services, digital transformation technologies, biohealth activities, and consumer products with operations in the United States, Singapore, Hong Kong, Australia, and South Korea. The Company operates in four business segments: Real Estate, Digital Transformation Technology, Biohealth, and other business activities, and it derives a majority of its revenue from the Real Estate segment.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Share on Social Networks: